Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Clinical trials news

Show

From To
New anti HIV drug dolutegravir is effective at low doses

The new anti-HIV integrase inhibitor dolutegravir is a highly potent drug. Alain Lafeuillade, a clinical researcher for 20 years in HIV disease, observed that Dolutegravir is highly effective alone in patients without integrase resistance. "Plasma viral load remained undetectable in my patients, and proviral HIV DNA in cells remained stable with only 50 mg 2 to 3 times a week," he said. He is proposing a low-dose dolutegravir monotherapy trial.

Published
21 January 2015
From
MMD Newswire
Gay men are better at predicting when they won’t have sex than when they will

A study in which a group of HIV-negative gay and bisexual men from New York were asked to predict each day whether they would have sex the

Published
12 January 2015
By
Gus Cairns
Pressure grows for Europe to subsidize HIV prevention drug Truvada

HIV-AIDS organizations are urging European health authorities to approve and subsidize the use of HIV prevention drug Truvada as infections slowly rise across the continent.

Published
02 December 2014
From
Deutsche Welle
START Study Could Change How We Look at HIV Treatment, and HIV Itself

Have you heard of the START (Strategic Timing of Antiretroviral Treatment) study? In my opinion, it is probably the most important study currently running. It generates strong views, both for and against initiating antiretroviral therapy early, but the results are likely to be surprising.

Published
25 November 2014
From
The Body
Groundbreaking HIV vaccine's effects were real – and could be made to work better

Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV

Published
13 November 2014
By
Gus Cairns
What are the barriers that could stop HIV treatment becoming HIV prevention?

One of the key strategies involved in trying to bring an end to the HIV epidemic is to increase the proportion of HIV-positive people on antiretroviral therapy

Published
12 November 2014
By
Gus Cairns
Misunderstanding of questions regarding anal sex in microbicide HIV prevention trial

There was widespread misunderstanding and misinterpretation of questions about anal sex being asked of participants in the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial,

Published
10 November 2014
By
Lesley Odendal
D-day for The Pill for HIV

The media coverage of the unexpectedly early success of two trials of pre-exposure prophylaxis - PrEP - has generally been positive, sometimes overly so. But I haven't seen anything that actually explains why the results of the PROUD and IPERGAY studies are so important, or why they represent a gear-change in the accelerating race towards the end of HIV.

Published
05 November 2014
From
Huffington Post
NIH Trial Tests Very Early Anti-HIV Therapy in HIV-Infected Newborns

​A new clinical trial is exploring whether giving anti-HIV therapy soon after birth to infants who became infected with HIV in the womb leads to remission of the virus, enabling the children eventually to stop treatment for an extended time period. The trial aims to build on the case of the 'Mississippi Baby'.

Published
05 November 2014
From
National Institute of Allergy and Infectious Diseases (NIAID) press release
High effectiveness seen in English PrEP trial

The Steering Committee* of the PROUD trial of pre-exposure prophylaxis (PrEP) in gay men in England announced today that participants currently on the deferred arm of the

Published
16 October 2014
By
Gus Cairns
← First12345...13Next →

Filter by country